Zimbabwe has turned down a substantial American health deal worth 367 million US dollars (£272m) spanning five years because of Washington's request for confidential biological samples.
The decision was revealed after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesperson has since stated that the US was demanding access to health data for research and commercial gain while refused to guarantee the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for further talks to reach a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
This development comes after a similar situation in neighbouring Kenya, where a high court blocked a related health funding agreement after concerns were filed about the safety of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.
As per reports, Sixteen African countries have so far signed similar agreements, representing over $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our citizens should a new pandemic arise."
National Interest and Global Health
He also noted that the American exit from the global health body and its push of bilateral deals were disrupting structures previously set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This mechanism is intended to guarantee that when a nation provides its data, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to further discussions with our US partners on how subsequent co-operation might be arranged in a manner that honours the independence and dignity of each country."
Health Experts Reaction
Medical experts stated it understood the government's concerns, but suggested that talks need to persist given that much of the country's HIV programmes were funded by foreign aid.
"Where technical issues exist, such as those relating to information security or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
This impasse highlights the ongoing debate between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.